We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
No unexpected safety signals were observed and it did not meet improved invasive disease-free survival in women with HR+, HER2- early breast cancer in the PENELOPE-B trial.